Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP548923.RAfAz2AkkNhjun-n83Q6WwseL74zBKecNqXx50-KkfrLk130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP548923.RAfAz2AkkNhjun-n83Q6WwseL74zBKecNqXx50-KkfrLk130_assertion type Assertion NP548923.RAfAz2AkkNhjun-n83Q6WwseL74zBKecNqXx50-KkfrLk130_head.
- NP548923.RAfAz2AkkNhjun-n83Q6WwseL74zBKecNqXx50-KkfrLk130_assertion description "[Understanding the molecular action of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, might allow us to perform more effective therapies for hormone-independent advanced prostate cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP548923.RAfAz2AkkNhjun-n83Q6WwseL74zBKecNqXx50-KkfrLk130_provenance.
- NP548923.RAfAz2AkkNhjun-n83Q6WwseL74zBKecNqXx50-KkfrLk130_assertion evidence source_evidence_literature NP548923.RAfAz2AkkNhjun-n83Q6WwseL74zBKecNqXx50-KkfrLk130_provenance.
- NP548923.RAfAz2AkkNhjun-n83Q6WwseL74zBKecNqXx50-KkfrLk130_assertion SIO_000772 16685379 NP548923.RAfAz2AkkNhjun-n83Q6WwseL74zBKecNqXx50-KkfrLk130_provenance.
- NP548923.RAfAz2AkkNhjun-n83Q6WwseL74zBKecNqXx50-KkfrLk130_assertion wasDerivedFrom befree-2016 NP548923.RAfAz2AkkNhjun-n83Q6WwseL74zBKecNqXx50-KkfrLk130_provenance.
- NP548923.RAfAz2AkkNhjun-n83Q6WwseL74zBKecNqXx50-KkfrLk130_assertion wasGeneratedBy ECO_0000203 NP548923.RAfAz2AkkNhjun-n83Q6WwseL74zBKecNqXx50-KkfrLk130_provenance.